Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes

NCT00510276 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00510276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes
Lead sponsor
Eli Lilly and Company
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2007
Completion date
February 28, 2009
Enrollment
445 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder